Quest Diagnostics Inc Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Quest Diagnostics Inc (DGX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$557.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-21.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2023-02-21
- Quest Diagnostics Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2018-03-31 was -$13.00M.
- Quest Diagnostics Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2017-03-31 was -$17.00M.
- Quest Diagnostics Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$557.00M.
- Quest Diagnostics Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was -$286.00M.
- Quest Diagnostics Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was -$34.00M, a 103.22% decline from fiscal 2019.
- Quest Diagnostics Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was $1.06B.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$557.00M 10-K · filed 2023-02-21 | |||
| 2021-12-31 | -$286.00M 10-K · filed 2023-02-21 | |||
| 2020-12-31 | -$34.00M 10-K · filed 2023-02-21 | |||
| 2019-12-31 | $1.06B 10-K · filed 2022-02-28 | |||
| 2018-12-31 | -$2.00M 10-K · filed 2021-02-22 | |||
| 2018-09-30 | $126.00M 10-Q · filed 2018-10-24 | |||
| 2018-06-30 | -$5.00M 10-Q · filed 2018-07-25 | |||
| 2018-03-31 | -$13.00M 10-Q · filed 2018-04-20 | |||
| 2017-12-31 | -$247.00M 10-K · filed 2020-02-20 | |||
| 2017-09-30 | -$34.00M 10-Q · filed 2018-10-24 | |||
| 2017-06-30 | -$70.00M 10-Q · filed 2018-07-25 | |||
| 2017-03-31 | -$17.00M 10-Q · filed 2018-04-20 | |||
| 2016-12-31 | $251.00M 10-K · filed 2019-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |